Probiotics  ||| S:0 E:11 ||| NNP
and  ||| S:11 E:15 ||| CC
Helicobacter  ||| S:15 E:28 ||| NNP
pylori  ||| S:28 E:35 ||| JJ
infection  ||| S:35 E:45 ||| NN
in  ||| S:45 E:48 ||| IN
children  ||| S:48 E:57 ||| NNS
Approximately  ||| S:57 E:71 ||| RB
50  ||| S:71 E:74 ||| CD
percent  ||| S:74 E:82 ||| NN
of  ||| S:82 E:85 ||| IN
the  ||| S:85 E:89 ||| DT
world  ||| S:89 E:95 ||| NN
population  ||| S:95 E:106 ||| NN
is  ||| S:106 E:109 ||| VBZ
infected  ||| S:109 E:118 ||| VBN
with  ||| S:118 E:123 ||| IN
Helicobacter  ||| S:123 E:136 ||| NNP
pylori  ||| S:136 E:143 ||| NNS
( ||| S:143 E:144 ||| -LRB-
H.  ||| S:144 E:147 ||| NNP
pylori ||| S:147 E:153 ||| CD
) ||| S:153 E:154 ||| -RRB-
,  ||| S:154 E:156 ||| ,
with  ||| S:156 E:161 ||| IN
the  ||| S:161 E:165 ||| DT
highest  ||| S:165 E:173 ||| JJS
prevalence  ||| S:173 E:184 ||| JJ
rates  ||| S:184 E:190 ||| NNS
in  ||| S:190 E:193 ||| IN
developing  ||| S:193 E:204 ||| VBG
countries ||| S:204 E:213 ||| NNS
.  ||| S:213 E:215 ||| .
The  ||| S:215 E:219 ||| DT
current  ||| S:219 E:227 ||| JJ
guidelines  ||| S:227 E:238 ||| NNS
suggest  ||| S:238 E:246 ||| VBP
the  ||| S:246 E:250 ||| DT
use  ||| S:250 E:254 ||| NN
of  ||| S:254 E:257 ||| IN
triple  ||| S:257 E:264 ||| JJ
therapy  ||| S:264 E:272 ||| NN
as  ||| S:272 E:275 ||| IN
first  ||| S:275 E:281 ||| JJ
choice  ||| S:281 E:288 ||| NN
treatment  ||| S:288 E:298 ||| NN
of  ||| S:298 E:301 ||| IN
Helicobacter  ||| S:301 E:314 ||| NNP
pylori  ||| S:314 E:321 ||| JJ
infection ||| S:321 E:330 ||| NN
,  ||| S:330 E:332 ||| ,
although  ||| S:332 E:341 ||| IN
the  ||| S:341 E:345 ||| DT
eradication  ||| S:345 E:357 ||| JJ
failure  ||| S:357 E:365 ||| NN
rate  ||| S:365 E:370 ||| NN
is  ||| S:370 E:373 ||| VBZ
more  ||| S:373 E:378 ||| JJR
than  ||| S:378 E:383 ||| IN
30  ||| S:383 E:386 ||| CD
percent ||| S:386 E:393 ||| NN
.  ||| S:393 E:395 ||| .
Current  ||| S:395 E:403 ||| JJ
interest  ||| S:403 E:412 ||| NN
in  ||| S:412 E:415 ||| IN
probiotics  ||| S:415 E:426 ||| NN
as  ||| S:426 E:429 ||| IN
therapeutic  ||| S:429 E:441 ||| JJ
agents  ||| S:441 E:448 ||| NNS
against  ||| S:448 E:456 ||| IN
Helicobacter  ||| S:456 E:469 ||| NNP
pylori  ||| S:469 E:476 ||| NN
is  ||| S:476 E:479 ||| VBZ
stimulated  ||| S:479 E:490 ||| VBN
by  ||| S:490 E:493 ||| IN
the  ||| S:493 E:497 ||| DT
increasing  ||| S:497 E:508 ||| JJ
resistance  ||| S:508 E:519 ||| NN
of  ||| S:519 E:522 ||| IN
pathogenic  ||| S:522 E:533 ||| JJ
bacteria  ||| S:533 E:542 ||| NNS
to  ||| S:542 E:545 ||| TO
antibiotics ||| S:545 E:556 ||| VB
,  ||| S:556 E:558 ||| ,
thus  ||| S:558 E:563 ||| RB
the  ||| S:563 E:567 ||| DT
interest  ||| S:567 E:576 ||| NN
for  ||| S:576 E:580 ||| IN
alternative  ||| S:580 E:592 ||| JJ
therapies  ||| S:592 E:602 ||| NN
is  ||| S:602 E:605 ||| VBZ
a  ||| S:605 E:607 ||| DT
real  ||| S:607 E:612 ||| JJ
actual  ||| S:612 E:619 ||| JJ
topic ||| S:619 E:624 ||| NN
.  ||| S:624 E:626 ||| .
Available  ||| S:626 E:636 ||| JJ
data  ||| S:636 E:641 ||| NNS
in  ||| S:641 E:644 ||| IN
children  ||| S:644 E:653 ||| NNS
indicate  ||| S:653 E:662 ||| VBP
that  ||| S:662 E:667 ||| IN
probiotics  ||| S:667 E:678 ||| NNS
seem  ||| S:678 E:683 ||| VBP
to  ||| S:683 E:686 ||| TO
be  ||| S:686 E:689 ||| VB
efficacious  ||| S:689 E:701 ||| VBN
for  ||| S:701 E:705 ||| IN
the  ||| S:705 E:709 ||| DT
prevention  ||| S:709 E:720 ||| NN
of  ||| S:720 E:723 ||| IN
antibiotic  ||| S:723 E:734 ||| NN
associated  ||| S:734 E:745 ||| VBN
side-effects ||| S:745 E:757 ||| JJ
,  ||| S:757 E:759 ||| ,
and  ||| S:759 E:763 ||| CC
might  ||| S:763 E:769 ||| MD
be  ||| S:769 E:772 ||| VB
of  ||| S:772 E:775 ||| IN
help  ||| S:775 E:780 ||| NN
for  ||| S:780 E:784 ||| IN
the  ||| S:784 E:788 ||| DT
prevention  ||| S:788 E:799 ||| NN
of  ||| S:799 E:802 ||| IN
Helicobacter  ||| S:802 E:815 ||| NNP
pylori  ||| S:815 E:822 ||| NN
complications  ||| S:822 E:836 ||| NNS
by  ||| S:836 E:839 ||| IN
decreasing  ||| S:839 E:850 ||| FW
Helicobacter  ||| S:850 E:863 ||| FW
pylori  ||| S:863 E:870 ||| FW
density  ||| S:870 E:878 ||| FW
and  ||| S:878 E:882 ||| CC
gastritis ||| S:882 E:891 ||| NN
,  ||| S:891 E:893 ||| ,
and  ||| S:893 E:897 ||| CC
for  ||| S:897 E:901 ||| IN
the  ||| S:901 E:905 ||| DT
prevention  ||| S:905 E:916 ||| NN
of  ||| S:916 E:919 ||| IN
Helicobacter  ||| S:919 E:932 ||| NNP
pylori  ||| S:932 E:939 ||| NN
colonization  ||| S:939 E:952 ||| NNS
or  ||| S:952 E:955 ||| CC
re-infection  ||| S:955 E:968 ||| JJ
by  ||| S:968 E:971 ||| IN
inhibiting  ||| S:971 E:982 ||| JJ
adhesion  ||| S:982 E:991 ||| NN
to  ||| S:991 E:994 ||| TO
gastric  ||| S:994 E:1002 ||| VB
epithelial  ||| S:1002 E:1013 ||| JJ
cells ||| S:1013 E:1018 ||| NNS
.  ||| S:1018 E:1020 ||| .
There  ||| S:1020 E:1026 ||| EX
is  ||| S:1026 E:1029 ||| VBZ
no  ||| S:1029 E:1032 ||| DT
clear  ||| S:1032 E:1038 ||| JJ
evidence  ||| S:1038 E:1047 ||| NN
that  ||| S:1047 E:1052 ||| IN
probiotics  ||| S:1052 E:1063 ||| NNS
may  ||| S:1063 E:1067 ||| MD
increase  ||| S:1067 E:1076 ||| VB
the  ||| S:1076 E:1080 ||| DT
Helicobacter  ||| S:1080 E:1093 ||| NNP
pylori  ||| S:1093 E:1100 ||| VBD
eradication  ||| S:1100 E:1112 ||| JJ
rate ||| S:1112 E:1116 ||| NN
.  ||| S:1116 E:1118 ||| .
